ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ibrutinib

Also written as “Ibrutinib”, “PCI-32765” and “PCI-32765 (Ibrutinib)”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Waldenstrom Macroglobulinemia · Lymphoma, Large B-Cell, Diffuse · Multiple Myeloma, led by 5 companies.

Drug pageIbrutinib: every studyMany companies study it; this page follows only the 74 they lead. All 264 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 14, 201774 company-led studies, 6 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only364 open or runningphase 4since Jun 14, 2017May 14, 2012Dec 31, 2026phase 3 · NCT01804686
AbbVieits history only341 open or runningphase 4since Jun 5, 2017Feb 20, 2009May 10, 2027phase 4 · NCT03229200
Novartisits history only21 open or runningphase 2since May 21, 2019Mar 13, 2019Jun 30, 2027phase 2 · NCT03960840
BeOne Medicines10 open or runningphase 3since Feb 7, 2017Feb 7, 2017none ahead
Oncternal Therapeuticsits history only10 open or runningphase 3since Jun 9, 2022Jun 9, 2022none ahead

Also a collaborator on its studies: Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of BeOne Medicines only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 7, 2017First study: phase 3 study in Waldenstrom MacroglobulinemiaFirst studyNCT03053440 · 201 enrolled · United States, Australia, Czechia and more

TargetBeta

BTK →read by rule
“An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

The one study BeOne Medicines leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03053440Waldenstrom Macroglobulinemia · United States, Australia, Czechia and more3CompletedJun 21, 2022201

How it is read

Names in the registry

  • “Ibrutinib”, 49 entries
  • “PCI-32765”, 10 entries
  • “ibrutinib”, 6 entries
  • “PCI-32765 (Ibrutinib)”, 2 entries
  • “SNX-5422 plus ibrutinib”, 2 entries

Codes read as this program: PCI32765.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.